Abstract |
Cancer is a complex disease since it is adaptive in such a way that it can promote proliferation and invasion by means of an overactive cell cycle and in turn cellular division which is targeted by antimitotic drugs that are highly validated chemotherapy agents. However, antimitotic drug cytotoxicity to non-tumorigenic cells and multiple cancer resistance developed in response to drugs such as taxanes and vinca alkaloids are obstacles faced in both the clinical and basic research field to date. In this review, the classes of antimitotic compounds, their mechanisms of action and cancer cell resistance to chemotherapy and other limitations of current antimitotic compounds are highlighted, as well as the potential of novel 17-β estradiol analogs as cancer treatment.
|
Authors | Rustelle Janse van Vuuren, Michelle H Visagie, Anne E Theron, Annie M Joubert |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 76
Issue 6
Pg. 1101-12
(Dec 2015)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 26563258
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antimitotic Agents
- Biomarkers, Tumor
- Taxoids
- Vinca Alkaloids
|
Topics |
- Antimitotic Agents
(classification, therapeutic use)
- Apoptosis
(drug effects)
- Biomarkers, Tumor
(metabolism)
- Cell Cycle
(drug effects)
- Cell Proliferation
(drug effects)
- Drug Resistance, Neoplasm
- Humans
- Neoplasms
(drug therapy, metabolism)
- Taxoids
(therapeutic use)
- Vinca Alkaloids
(therapeutic use)
|